An adenovirus-based vaccine manufacturing technology platform for mucosal or parenteral immunization against poultry diseases in sub-Saharan Africa


Developing novel vaccine technology platforms to respond to emergency situations such as pandemic threats or zoonotic diseases is a worldwide high priority. Public health at a global scale is frequently influenced by the risk of transmission of infectious diseases from wildlife and domestic animals. Thus, veterinary vaccination and animal health monitoring are highly relevant for the deployment of a preventative global policy in the context of “one world, one health”. In regions such as Sub-Saharan Africa, farmers’ activities are frequently affected by the impact of diseases in poultry such as avian influenza and Newcastle disease (ND). ND is one of the most critical, with several outbreaks per year. Currently, protection is provided by vaccination with live vaccines produced only in embryonated eggs, with limitations related to egg supply and the possibility of virus shedding by vaccinated poultry, leading to disease in non-vaccinated birds. The purpose of this work was to develop an adenovirus (Ad) vectored vaccine platform technology suitable for the rapid adaptation to ND or other avian viral threats. The project involved the phylogenetic analysis of local isolates of Newcastle disease virus (NDV) and the construction of adenoviral vectors expressing the F and HN antigens from NDV genotype VI, either as individual antigens or in bicistronic vectors. Remarkably, adenoviral rescue and generation of primary stocks was streamlined by developing a novel procedure for single step amplification in suspension cultures.

Vaccine Technology VIII, ECI Symposium Series 2022
Omar Farnos
Staff (Research Associate)